--- title: "Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 10-Q: FY2025 Q3 Revenue: USD 17.63 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/265944189.md" datetime: "2025-11-14T13:48:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/265944189.md) - [en](https://longbridge.com/en/news/265944189.md) - [zh-HK](https://longbridge.com/zh-HK/news/265944189.md) --- # Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 10-Q: FY2025 Q3 Revenue: USD 17.63 M Revenue: As of FY2025 Q3, the actual value is USD 17.63 M. EPS: As of FY2025 Q3, the actual value is USD 0.11. EBIT: As of FY2025 Q3, the actual value is USD -4.805 M. ### Journey Medical Corporation (Journey) - **Net Revenue**: $17.6 million for the three months ended September 30, 2025, compared to $14.6 million for the same period in 2024. - **Cost of Goods Sold**: $5.8 million for the three months ended September 30, 2025, compared to $4.5 million for the same period in 2024. - **Amortization of Acquired Intangible Assets**: $1.1 million for the three months ended September 30, 2025, compared to $0.8 million for the same period in 2024. - **Research and Development Expenses**: $0.3 million for the three months ended September 30, 2025, compared to $0.8 million for the same period in 2024. - **Selling, General and Administrative Expenses**: $12.1 million for the three months ended September 30, 2025, compared to $11.4 million for the same period in 2024. - **Stock-Based Compensation - Selling, General and Administrative**: $1.9 million for the three months ended September 30, 2025, compared to $1.5 million for the same period in 2024. ### Avenue Therapeutics (Avenue) - **Research and Development Expenses**: $0.2 million for the three months ended September 30, 2025, compared to $2.3 million for the same period in 2024. - **Selling, General and Administrative Expenses**: $0.5 million for the three months ended September 30, 2025, compared to $0.8 million for the same period in 2024. - **Stock-Based Compensation - Selling, General and Administrative**: $0.1 million for the three months ended September 30, 2025, compared to $0.2 million for the same period in 2024. ### Mustang Bio, Inc. (Mustang) - **Research and Development Expenses**: - $0.3 million for the three months ended September 30, 2025, compared to $0.1 million for the same period in 2024. - **Selling, General and Administrative Expenses**: $1.0 million for the three months ended September 30, 2025, compared to $1.4 million for the same period in 2024. - **Stock-Based Compensation - Selling, General and Administrative**: $0.02 million for the three months ended September 30, 2025, compared to $0.05 million for the same period in 2024. ### Fortress Biotech, Inc. (Fortress) - **Research and Development Expenses**: $0.1 million for the three months ended September 30, 2025, compared to - $0.1 million for the same period in 2024. - **Selling, General and Administrative Expenses**: $3.9 million for the three months ended September 30, 2025, compared to $5.0 million for the same period in 2024. - **Stock-Based Compensation - Selling, General and Administrative**: $1.0 million for the three months ended September 30, 2025, compared to $2.5 million for the same period in 2024. ### Consolidated - **Net Revenue**: $17.6 million for the three months ended September 30, 2025, compared to $14.6 million for the same period in 2024. - **Cost of Goods Sold**: $5.8 million for the three months ended September 30, 2025, compared to $4.5 million for the same period in 2024. - **Amortization of Acquired Intangible Assets**: $1.1 million for the three months ended September 30, 2025, compared to $0.8 million for the same period in 2024. - **Research and Development Expenses**: $0.2 million for the three months ended September 30, 2025, compared to $9.4 million for the same period in 2024. - **Selling, General and Administrative Expenses**: $17.4 million for the three months ended September 30, 2025, compared to $22.0 million for the same period in 2024. - **Stock-Based Compensation - Selling, General and Administrative**: $3.0 million for the three months ended September 30, 2025, compared to $5.4 million for the same period in 2024. - **Interest Income**: $0.7 million for the three months ended September 30, 2025, compared to $0.6 million for the same period in 2024. - **Interest Expense and Financing Fee**: $2.7 million for the three months ended September 30, 2025, compared to $6.2 million for the same period in 2024. - **Other Income**: $17.7 million for the three months ended September 30, 2025, compared to $1.1 million for the same period in 2024. - **Net Income (Loss) Attributable to Fortress**: $5.9 million for the three months ended September 30, 2025, compared to - $12.9 million for the same period in 2024. ### Future Outlook and Strategy - **Journey Medical Corporation**: Journey plans to continue expanding the payer coverage for Emrosi and other marketed products, focusing on increasing market penetration and sales. - **Avenue Therapeutics**: Avenue will focus on advancing its clinical development programs and exploring strategic partnerships to support its pipeline. - **Mustang Bio, Inc.**: Mustang will continue to streamline its operations, focusing on advancing its clinical programs and managing costs effectively. - **Fortress Biotech, Inc.**: Fortress will continue to leverage its expertise to support its subsidiaries and partner companies, exploring strategic arrangements to accelerate funding and development. ### Related Stocks - [FBIOP.US](https://longbridge.com/en/quote/FBIOP.US.md) ## Related News & Research - [Argenx (ENXTBR:ARGX) Stock Valuation After Expanded FDA Approval For Vyvgart And Pipeline Progress](https://longbridge.com/en/news/289661572.md) - [Mark Zuckerberg's Net Worth Crashes $31 Billion This Year, But Analysts Still Bullish on Meta](https://longbridge.com/en/news/289670977.md) - [Should Alcoa’s Quebec Wharf 17 Logistics Upgrade Prompt Reassessment From Alcoa (AA) Investors?](https://longbridge.com/en/news/289661460.md) - [Langdon Equity Partners Acquires New Holdings in Goosehead Insurance $GSHD](https://longbridge.com/en/news/289662511.md) - [UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 126,120 Shares of McKesson Corporation $MCK](https://longbridge.com/en/news/289662493.md)